Neuroblastoma: evolving therapies for a disease with many faces - PubMed (original) (raw)
Review
Neuroblastoma: evolving therapies for a disease with many faces
Robert E Goldsby et al. Paediatr Drugs. 2004.
Abstract
Neuroblastoma is the most common extra-cranial solid tumor in children and has a heterogeneous clinical presentation and course. Clinical and biologic features of this disease have been used to develop risk-based therapy. Patients with low-risk disease can be treated with surgery alone. Patients with intermediate-risk features have an excellent prognosis after treatment with surgery and a relatively short course of standard dose chemotherapy. Unfortunately, most children with neuroblastoma present with advanced disease. More than 60% of patients with high-risk features will succumb to their disease despite intensive therapy including a myeloablative consolidation. Research efforts to understand the biologic basis of neuroblastoma and to identify new, more effective therapies are essential to improve the outcome for these children.
Similar articles
- Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.
Owens C, Irwin M. Owens C, et al. Crit Rev Clin Lab Sci. 2012 May-Jun;49(3):85-115. doi: 10.3109/10408363.2012.683483. Crit Rev Clin Lab Sci. 2012. PMID: 22646747 Review. - Neuroblastoma: biology, prognosis, and treatment.
Park JR, Eggert A, Caron H. Park JR, et al. Hematol Oncol Clin North Am. 2010 Feb;24(1):65-86. doi: 10.1016/j.hoc.2009.11.011. Hematol Oncol Clin North Am. 2010. PMID: 20113896 Review. - Neuroblastoma: clinical and biological approach to risk stratification and treatment.
Tolbert VP, Matthay KK. Tolbert VP, et al. Cell Tissue Res. 2018 May;372(2):195-209. doi: 10.1007/s00441-018-2821-2. Epub 2018 Mar 23. Cell Tissue Res. 2018. PMID: 29572647 Free PMC article. Review. - Management of Neuroblastoma: ICMR Consensus Document.
Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, Prasad M, Kapoor G, Radhakrishnan V, Laskar S, Kaur T, Rath GK, Bakhshi S. Bansal D, et al. Indian J Pediatr. 2017 Jun;84(6):446-455. doi: 10.1007/s12098-017-2298-0. Epub 2017 Apr 3. Indian J Pediatr. 2017. PMID: 28367616 Review. - Neuroblastoma: biology, prognosis, and treatment.
Park JR, Eggert A, Caron H. Park JR, et al. Pediatr Clin North Am. 2008 Feb;55(1):97-120, x. doi: 10.1016/j.pcl.2007.10.014. Pediatr Clin North Am. 2008. PMID: 18242317 Review.
Cited by
- Contrast-enhanced computed tomography radiomics in predicting primary site response to neoadjuvant chemotherapy in high-risk neuroblastoma.
Wang H, Qin J, Chen X, Zhang T, Zhang L, Ding H, Pan Z, He L. Wang H, et al. Abdom Radiol (NY). 2023 Mar;48(3):976-986. doi: 10.1007/s00261-022-03774-0. Epub 2022 Dec 26. Abdom Radiol (NY). 2023. PMID: 36571609 - A novel minimal residual disease model of neuroblastoma in mice.
Jackson JR, Kim Y, Seeger RC, Kim ES. Jackson JR, et al. J Pediatr Surg. 2016 Jun;51(6):991-4. doi: 10.1016/j.jpedsurg.2016.02.066. Epub 2016 Mar 4. J Pediatr Surg. 2016. PMID: 26995512 Free PMC article. - High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B, Kremer LC, van Dalen EC. Yalçin B, et al. Cochrane Database Syst Rev. 2015 Oct 5;2015(10):CD006301. doi: 10.1002/14651858.CD006301.pub4. Cochrane Database Syst Rev. 2015. PMID: 26436598 Free PMC article. Review. - Quantitative nuclear proteomics identifies that miR-137-mediated EZH2 reduction regulates resveratrol-induced apoptosis of neuroblastoma cells.
Ren X, Bai X, Zhang X, Li Z, Tang L, Zhao X, Li Z, Ren Y, Wei S, Wang Q, Liu C, Ji J. Ren X, et al. Mol Cell Proteomics. 2015 Feb;14(2):316-28. doi: 10.1074/mcp.M114.041905. Epub 2014 Dec 11. Mol Cell Proteomics. 2015. PMID: 25505154 Free PMC article. - Intermittent hypoxia effect on osteoclastogenesis stimulated by neuroblastoma cells.
Bhaskara VK, Mohanam I, Gujrati M, Mohanam S. Bhaskara VK, et al. PLoS One. 2014 Aug 22;9(8):e105555. doi: 10.1371/journal.pone.0105555. eCollection 2014. PLoS One. 2014. PMID: 25148040 Free PMC article. Retracted.
References
- Med Pediatr Oncol. 2001 Jan;36(1):169-76 - PubMed
- Cancer Res. 1995 Dec 1;55(23):5681-6 - PubMed
- Science. 1984 Jun 8;224(4653):1121-4 - PubMed
- Lancet. 1996 Dec 21-28;348(9043):1682-7 - PubMed
- J Clin Oncol. 1998 Apr;16(4):1256-64 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical